

Application No.: 10/540,348


9 of 10

Remarks/Arguments

Applicants have amended the specification to provide the priority claim.

The claims have been amended to in view of a citation on the International Search Report, namely Database Accession number 2002:2408531, Order No. 7H-015, "Interchim Intermediates," 9 July 2002 and to otherwise place the claims in an appropriate U.S. format. Additional claims have been added, support for which can be found in the specification as indicated below.

The above citation discloses the compound:



i.e. 4-[-2-(6-phenylimidazo[2,1-b][1,3-thiazol-5-yl]ethenyl]-2-pyrimidinamine which falls within the scope of originally presented claim 1.

This appears to be a compound commercially available from "Interchim Intermediates". There is no disclosed activity for the compound. Claim 1 has been amended to expressly remove this compound from the scope of claim 1 by adding the language "provided the compound is not 4-[-2-(6-phenylimidazo[2,1-b][1,3-thiazol-5-yl]ethenyl]-2-pyrimidinamine" at the end of the claim.

New claims 6 through 12 have been added, support for which can be found in the application as follows:

Claim 6 - page 17, lines 9-10.

Claim 7 - page 17, line 13.

Claim 8 - page 17, lines 15-17.

Claim 9 - page 17, lines 21-22.

Claim 10 - page 17, line 25 and page 18 lines 1-3.

Claim 11 - original claim 4, and page 32, lines 22-25.

Claim 28 - original claim 5, and page 32, lines 26-29.

It is respectfully submitted no new matter has been added by the instant amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Application No.: 10/540,348

10 of 10

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100877-1P US.

Respectfully submitted,



Name: Carol A. Loeschorn
Dated: March 13, 2006
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451